(IN BRIEF) Novartis has announced its acquisition of Anthos Therapeutics, a Boston-based biopharmaceutical company focused on developing abelacimab, an investigational monoclonal antibody currently in Phase 3 trials for preventing stroke and systemic embolism in patients with atrial fibrillation. This acquisition … Read the full press release
Posted in Business, Financial, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged abelacimab, acquisition, Anthos Therapeutics, anticoagulation, atrial fibrillation, biopharmaceutical company, Blackstone Life Sciences, bleeding reduction, Boston, cancer-associated thrombosis, cardiovascular, cardiovascular therapeutic area, clinical-stage, David Soergel, Factor XI inhibition, Fast Track Designation, FDA, medical research, Novartis, partnership, Phase 3 trials, regulatory milestones, Shreeram Aradhye, stroke prevention, systemic embolism, therapeutic focus, thrombosis
(IN BRIEF) A recent comprehensive review published in The Lancet Regional Health Europe offers insights into the risk factors and management strategies for atrial fibrillation (AF), a prevalent heart rhythm disorder affecting millions globally. Conducted by researchers from the University … Read the full press release
Posted in Business, Education, Environment, Financial, Healthcare, Industrial, Investment, Management, News, Science, Technology, United Kingdom
Tagged atrial fibrillation, Dr Eduard Shantsila, Management, Professor Deirdre Lane, Professor Gregory Lip, risk factors, Seoul National University College of Medicine, The Lancet, University of Liverpool
(IN BRIEF) The EHRA 2023 scientific congress of the European Heart Rhythm Association (EHRA), a branch of the European Society of Cardiology (ESC), will be held from April 16 to 18 in Barcelona, Spain, as well as online. The congress … Read the full press release
Posted in Artificial Intelligence (AI), Education, France, Healthcare, Management, Pharma & Biotech, Science, Spain, Technology
Tagged AI, artificial-intelligence, atrial fibrillation, cardiac devices, charging of electric cars, EHRA, EHRA 2023, ESC, European Heart Rhythm Association, European Society of Cardiology, heart rhythm disorders, heart rhythm management, Professor Andrea Sarkozy, Professor Serge Boveda, statins
For Non-US/Non-UK/Non-Canadian Media New analyses highlight undertreatment of high-risk AF patients1,2 First Phase II data demonstrating anticoagulant prescribing patterns in North America now available from GLORIA™-AF Registry Program Results presented at American College of Cardiology 64th Annual Scientific Session & … Read the full press release
CAMBRIDGE, UK, 2-9-2014 — /EuropaWire/ — XENTION LTD (“Xention”), the Cambridge-based biopharmaceutical company specialising in the discovery and development of ion channel-modulating drugs developing anti-arrhythmic drugs, announced today that the phase 2 development of its lead atrial fibrillation programme (“AF”) is underway. … Read the full press release
27-8-2013 — /EuropaWire/ — The fourth AFNET/EHRA consensus conference was convened to discuss how to identify the underlying main pathophysiologies of AF in individual patients so that more targeted therapies could be developed to close the mortality gap. Amsterdam, The Netherlands – Tuesday 27 … Read the full press release
Posted in Education, Healthcare, Netherlands, Pharma & Biotech, Science, United Kingdom
Tagged acute revascularization procedures, AFNET, artery thrombotic blockage, atrial fibrillation, atrial fibrillation (AF) mortality gap, biomarkers, coronary plaques, ESC Congress 2013, ESC consensus paper, European Heart Rhythm Association, European Society of Cardiology, myocardial infarction, pathophysiology causing the disease, personalised cardiology, Professor Paulus Kirchhof, Stroke risk scores, The Atrial Fibrillation competence NETwork, The German Competence Network on Atrial Fibrillation, thrombotic blockage
For media outside of the US, the UK & Canada only Ingelheim, Germany, 26-8-2013 — /EuropaWire/ — Boehringer Ingelheim today announced the upcoming presentation of new data on the novel oral anticoagulant (NOAC) Pradaxa® (dabigatran etexilate) during the ESC Congress 2013 organised … Read the full press release
Posted in Germany, Healthcare, Pharma & Biotech, Science
Tagged atrial fibrillation, atrial fibrillation patient populations, Boehringer Ingelheim, dabigatran etexilate, ESC Congress 2013, ESC Congress 2013 in Amsterdam, European Society of Cardiology, Ingelheim, novel oral anticoagulant (NOAC) Pradaxa®, optimal stroke protection, pivotal RE-LY® trial, Pradaxa®, prevention of stroke and systemic embolism, Professor Klaus Dugi, Sara McClelland
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?